4D-710

4DMT's 4D-150 Shows Promise in Wet AMD and DME, Advances to Phase 3 Trials

4 months ago

• 4DMT's 4D-150 demonstrates sustained delivery of anti-VEGF, reducing the need for frequent injections in wet AMD and DME patients. • SPECTRA trial data shows 4D-150 leads to significant visual acuity gains and CST reduction in DME, with FDA alignment for Phase 3. • PRISM trial results reveal a substantial reduction in injection burden for wet AMD patients, with durable aflibercept expression over two years. • 4DMT's 4D-150 leverages the R100 vector for single-injection treatment, potentially transforming care for millions with retinal diseases.

4DMT Prioritizes 4D-150 and 4D-710, Extends Cash Runway into 2028

4 months ago

• 4DMT is focusing its pipeline on 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosis, leveraging their strong clinical proof of concept. • Phase 3 trials (4FRONT-1 and 4FRONT-2) for 4D-150 in wet AMD are set to begin in Q1 and Q3 2025, respectively, with topline data expected in H2 2027. • The company's cash runway has been extended to 2028, supported by $506M in cash reserves and strategic resource allocation. • 4DMT will discontinue development of early-stage programs like 4D-110 for choroideremia and 4D-125 for X-linked retinitis pigmentosa.

4DMT's 4D-150 Shows Promise in Wet AMD and DME, Advances to Phase 3 Trials

4DMT Prioritizes 4D-150 and 4D-710, Extends Cash Runway into 2028

Drug Development Updates